# Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice

**URL:** <https://forum.painresearcher.net/t/long-lasting-analgesia-via-targeted-in-situ-repression-of-nav1-7-in-mice/819>\
**Category:** Journal Club\
**Created:** [March 13, 2021, 4:25am UTC](https://forum.painresearcher.net/t/long-lasting-analgesia-via-targeted-in-situ-repression-of-nav1-7-in-mice/819 "2021-03-13T04:25:07Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![achamess](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/achamess/32/534_2.png) [@achamess](https://forum.painresearcher.net/u/achamess)\
**Post date:** [March 13, 2021, 4:25am UTC](https://forum.painresearcher.net/t/long-lasting-analgesia-via-targeted-in-situ-repression-of-nav1-7-in-mice/819/1 "2021-03-13T04:25:07Z")

</div>

> **[Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice](https://stm.sciencemag.org/content/13/584/eaay9056)**
>
> Opioids are the current standard of care for the treatment of chronic pain. However, they have severe side effects. Recent data have shown that loss-of-function mutations in the sodium channel NaV1.7 cause insensitivity to pain. Here, Moreno et al....

Nice work @mamocol and team